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Background/aims: The apical sodium dependent bile acid transporter ASBT (SLC10A2) contributes
substantially to the enterohepatic circulation of bile acids by their reabsorption from the intestine. In the rat,
its adaptive regulation was observed in the kidneys, cholangiocytes, and terminal ileum after bile duct
ligation. Whether adaptive regulation of the human intestinal ASBT exists during obstructive cholestasis is
not known.
Methods: Human ASBT mRNA expression along the intestinal tract was analysed by real time polymerase
chain reaction in biopsies of 14 control subjects undergoing both gastroscopy and colonoscopy. Their
duodenal ASBT mRNA expression was compared with 20 patients with obstructive cholestasis.
Additionally, in four patients with obstructive cholestasis, duodenal ASBT mRNA expression was
measured after reconstitution of bile flow.
Results: Normalised ASBT expression in control subjects was highest (mean arbitrary units (SEM)) in the
terminal ileum (1010 (330)). Low ASBT expression was found in colonic segments (8.3 (5), 4.9 (0.9), 4.8
(1.7), and 1.1 (0.2) in the ascending, transverse, descending, and sigmoid colon, respectively). Duodenal
ASBT expression in control subjects (171.8 (20.3)) was found to be approximately fourfold higher
compared with patients with obstructive cholestasis (37.9 (6.5); p,0.0001). Individual ASBT mRNA
expression was inversely correlated with bile acid and bilirubin plasma concentrations. In four cholestatic
patients, average ASBT mRNA increased from 76 (18) before to 113 (18) after relief of cholestasis (NS).
Immunohistochemical assessment indicated that ASBT protein was expressed on the apical surface of
duodenal epithelial cells.
Conclusion: Obstructive cholestasis in humans leads to downregulation of ASBT mRNA expression in the
distal part of the human duodenum.
B
ile acids are amphipathic steroidal compounds derived
from the enzymatic catabolism of cholesterol in the liver
by cytochrome P450 isoform 7A1 (CYP7A1). In the small
intestine, bile acids emulsify dietary fats and lipid soluble
vitamins. They participate in the regulation of pancreatic
secretion and release of gastrointestinal peptides.1 Through
the coordinated action of several transport proteins expressed
in hepatocytes, cholangiocytes, as well as in enterocytes and
in proximal tubular cells of the kidney, an efficient
enterohepatic circulation of bile acids is maintained.2 One
of these transport proteins, the apical sodium dependent bile
acid transporter ASBT (SLC10A2) has been detected in the
ileum, caecum, and kidney3 and mediates the uptake of bile
acids from the lumen of the intestine, from renal tubules, and
from cholangiocytes. ASBT is a 348 amino acid protein that
transports conjugated and unconjugated bile acids with a
high efficiency.3 Subjects with mutations in the ASBT gene
suffer from congenital diarrhoea and steatorrhoea due to bile
acid malabsorption.4 Pharmacological inhibition of ASBT
leads to interruption of enterohepatic circulation of bile acids
with changes in cholesterol and bile acid homeostasis.5–9
Adaptive induction of asbt mRNA expression, transporter
protein, and transport activity was observed in cholic acid fed
rats10 whereas decreased asbt expression was found in the
ileum of bile duct ligated rats.11 In addition, in Wistar rats, a
marked reduction in asbt protein expression was observed in
microsomal membrane fractions from whole kidney after
ligation of the common bile duct (CBDL) with consequent
increased urinary bile acid excretion. These results indicate
that asbt is adaptively regulated in different tissues during
obstructive cholestasis in the rat.
Lanzini and colleagues12 studied the effects of cholestasis
on intestinal bile acid transport in 14 subjects with chronic
cholestasis due to primary biliary cirrhosis before and during
ursodeoxycholic acid (UDCA) administration. Prolonged
retention of the bile acid analogue 75Se-homocholic acid
taurine (75SeHCAT) in patients with primary biliary cirrhosis
was observed compared with healthy controls and patients
with Crohn’s disease. Retention of 75SeHCAT decreased with
UDCA treatment, inferring that luminal bile acid levels may
be involved in the regulation of ASBT gene regulation.
Virtually all bile salt transporter systems are subject to
extensive regulation, mainly at the level of gene transcrip-
tion. These regulatory mechanisms represent adaptive
responses to intracellular accumulation of bile salts and
other amphipathic molecules. However, little is known about
adaptive regulation of ASBT expression in humans. The aim
of this study was therefore to investigate expression of ASBT
in the duodenum of healthy subjects and compare the results
with patients with obstructive cholestasis. Because direct
analysis of ASBT gene expression in samples from the
Abbreviations: ASBT, apical sodium dependent bile acid transporter;
CBDL, common bile duct ligation; UDCA, ursodeoxycholic acid;
75SeHCAT, 75Se-homocholic acid taurine; MRP, multidrug resistance
associated protein; ERCP, endoscopic retrograde cholangiopancreat-
ography; PPARa, peroxisome proliferator activated receptor a
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terminal ileum cannot be performed in humans with
obstructive cholestasis for obvious ethical reasons, in the
first part of this study we analysed ASBT mRNA expression in
healthy subjects in different segments of the human
intestine. We found that ASBT mRNA was also expressed
in the duodenum but to a lesser extent than in the terminal
ileum.
Additionally, we analysed gene expression of multidrug
resistance associated protein 3 (MRP3), which is expressed
on the basolateral membrane of the enterocyte13 and which is
capable of transporting bile salts,14 as well as expression of
multidrug resistance associated protein 2 (MRP2). Human
duodenal MRP2 protein expression was downregulated
during cholestasis.15 Biopsies of the duodenum of patients
with obstructive cholestasis were obtained during therapeutic
endoscopic retrograde cholangiopancreatography (ERCP).
PATIENTS AND METHODS
Patients
Fourteen healthy subjects (seven males, seven females) were
enrolled into the first part of the study after giving informed
consent. The indication for combined upper and lower
gastrointestinal tract endoscopy was a cancer screening
programme. Biopsies were obtained from the duodenum,
terminal ileum, and from different defined regions of the
colon. In the second part of the study, 20 cholestatic patients
were enrolled after giving written informed consent. Biopsies
were obtained from the duodenum in these patients. Of 10
patients with obstructive tumours, four had carcinomas of
the pancreatic head, four had cholangiocarcinomas (Klatskin
tumour), and two had metastatic diseases. Ten patients had
benign diseases (eight patients with choledocholithiasis and
two patients with a benign stenosis of the common bile
duct). Obstructive jaundice was defined: (1) on the basis of
biochemical parameters (bilirubin, c-glutamyltransferase,
and alkaline phosphatase) and (2) on imaging procedures
(ultrasound and ERCP), demonstrating a dilated bile duct
system. All control patients had normal values of the above
parameters. Patients were only included if they were not
taking any medication known to affect ASBT, MRP2, or
MRP3 expression. Demographic details are given in table 1.
Materials
All chemicals were of the highest quality available and were
obtained from commercial sources.
Real time PCR analysis of human ASBT, MRP2, MRP3,
PPAR-a, and vil lin (VIL1) mRNA (TaqMan assay)
Using standard pinch forceps, four intestinal biopsies were
taken from each anatomical site (the distal part of the
duodenum, terminal ileum, and different segments of the
colon) during an interventional ERCP procedure (patients
with obstructive cholestasis) or during gastroscopy and
colonoscopy (control subjects). Biopsies were immediately
submerged in a tube with RNAlater (Ambion) and stored at
280 C˚ until further processing. For RNA isolation, two
biopsies from each donor were homogenised for 30 seconds
(Polytron PT 2100; Kinematika AG, Switzerland) and RNA
was extracted using the RNeasy Mini Kit (Qiagen GmbH,
Hilden, Germany) following the manufacturer’s instructions.
RNA was quantified with a GeneQuant photometer
(Pharmacia, Uppsala, Sweden). After DNase I digestion
(Gibco Life Technologies, Basel, Switzerland) 1.5 mg of total
RNA were reverse transcribed by Superscript (Gibco Life
Technologies) according to the manufacturer’s protocol,
using random hexamers as primers.
TaqMan analysis was carried out on a 7900HT sequence
detection system (Applied Biosystems, Rotkreuz,
Switzerland). Polymerase chain reaction (PCR) cycling
conditions were 10 minutes at 95 C˚ followed by 40 cycles of
15 seconds at 95 C˚ and one minute at 60 C˚. Each TaqMan
reaction contained 10 ng of cDNA in a total volume of 10 ml.
TaqMan Universal PCR Mastermix from Applied Biosystems
was used. Concentrations of primers and probes were
900 nM and 225 nM, respectively. They were designed
according to the guidelines of Applied Biosystems with help
of the Primer Express 2.0 software (corresponding sequences
are listed in table 2). Primers were synthesised by Invitrogen
(Basel, Switzerland) and probes by Eurogentec (Seraing,
Belgium). All samples were run in triplicate. TaqMan PCR
products were confirmed by sequencing (Microsynth GmbH,
Balgach, Switzerland). Non-reverse transcribed RNA served
as a negative control. No significant amplification was
observed in these samples.
For each sample, the number of gene transcripts (ASBT,
MRP2, MRP3, peroxisome proliferator activated receptor a
(PPARa)) and the number of villin transcripts were
determined. By calculating the ratio of gene/villin mRNA,
gene expression was normalised to enterocyte content.
Determination of villin, an enterocyte specific, constitutively
expressed protein, can be used to control for the variation in
enterocyte content in biopsies.16 17 For absolute quantification
we used external standard curves. Standards were gene
specific cDNA fragments that cover the Taqman primer/probe
area and were obtained by PCR amplification. For ASBT,
MRP2, and MRP3, we used cDNA from Caco-2 cells as a
template whereas for PPARa, cDNA from duodenal tissue
was used. Gene specific PCRs were performed with compo-
nents from Applied Biosystems (AmpliTaq Gold; 106 PCR
buffer, dNTPs, MgCl2). Each reaction contained 25 ng of
cDNA and 300 nM of each primer (corresponding sequences
are listed in table 3) in a total volume of 25 ml. Thermal
cycling was conducted using a Mastercycler personal from
Eppendorf (Hamburg, Germany). All PCR products were
purified by running a 1.5% agarose gel and a subsequent gel
extraction (gel extraction kit; Qiagen). Standards were
quantified using the PicoGreen reagent (Molecular Probes,
Eugene, Oregon, USA) and were checked by sequencing
(Microsynth GmbH, Balgach, Switzerland).
Standard curves were generated by plotting the obtained Ct
values (cycle number when a sample reaches the threshold)
Table 1 Patient characteristics of the two study groups
Characteristic Icteric patients (n = 20) Controls (n = 14) p Value
Age (y)* 67.4 (2.8) 59.8 (2.7) NS
BMI (kg/m2)* 24.1 (0.8) 28.4 (1.6) 0.015
Sex (M/F) 10/10 7/7 NS
Diagnosis 10 T/10 BS 3 G/3 O/8 U
Bilirubin (mmol/l) 235 (42–640) 11 (5–17) ,0.001
Bile acids (mmol/l) 122.6 (20.5–401) 1.7 (0.5–3.2) ,0.001
Values are mean (SEM).
BMI, body mass index; T, tumour; BS, biliary stone; G, mild gastritis; E, mild oesophagitis; U, macroscopically
unaffected mucosa.
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as a function of the log(10) of the corresponding dilution
factor and using linear regression. Curves were linear with
correlation coefficients of 0.996, 0.998, 0.999, 0.997, and
0.998 for ASBT, villin, MRP2, MRP3, and PPARa, respec-
tively. The corresponding PCR efficiencies (calculated as
10(1/2slope)21) were 93%, 95.5%, 89.1%, 95%, and 97.1%,
respectively. Each standard curve also included no template
controls.
The sensitivity of all TaqMan assays was found to be
adequate for quantifying all transcripts in the analysed
intestinal tissues. Only in samples from the sigmoid colon did
expression of ASBT mRNA appear to be so low that accurate
quantification of transcript numbers was not possible for all
biopsies. The precision of the ASBT determination was
assessed by measuring 10 aliquots of duodenal cDNA (each
in triplicates). The intra-assay coefficient of variation (CV)
was 4.69%. Interassay CV was not determined as for every
gene all samples could be placed onto one 384 well plate.
Accuracy of the method was determined by measuring a
standard with a known amount of template (n = 10 in
triplicates). Deviation of the mean value from the true value
was 14.85%.
Immunohistochemical assessment
For immunohistochemical assessment of ASBT expression in
human intestinal tissue, a polyclonal rabbit antihuman ASBT
(generous gift from Dr PA Dawson, Wake Forest University
Baptist Medical Center, Winston-Salem, North Carolina,
USA) was used. This antibody was raised against the carboxyl
terminal 39 amino acids of human ASBT that was expressed
as a glutathione S-transferase-ASBT fusion protein. The
human ASBT antibody has been previously used to measure
ASBT protein expression in human ileal biopsies.18
Human intestinal tissue was mounted in OCT compound
(Sakura Finetek, Zooterwoude, the Netherlands), frozen in
liquid nitrogen, and stored at 270 C˚. Sections (5 mm) of
human intestine were air dried overnight and a periodate-
lysine-paraformaldehyde solution (3%) was used for post
fixation. Then sections were washed with washing solution
(TBS/NaCl, Tween 0.05%) and incubated with goat serum
(Vectastain, Elite kit; Vector Laboratories, Burlingame,
California, USA) for 30 minutes at room temperature as
blocking solution. Tissue sections were incubated with a
1:400 dilution of the polyclonal rabbit antihuman ASBT
overnight at 4 C˚. Samples were washed three times with
washing solution and incubated with the goat antirabbit IgG
secondary antibody for 30 minutes at room temperature.
After three washes with the washing solution, a perhydral
solution (H2O2 (0.3%), sodium azide (0.1%) in phosphate
buffered saline) was used to destroy endogenous peroxidase
activity. Staining was performed with the avidin/biotinylated
enzyme complex (ABC method) according to the manufac-
turer’s instructions (Vectastain, Elite kit; Vector
Laboratories). For detection, 3-amino-9-ethylcarbazole,
which forms a red end product, was used (Biogenex, San
Ramon, California, USA). Sections, which served as negative
controls, were incubated only with the goat antirabbit IgG
secondary antibody. Biopsies from normal terminal ileum
were used as a positive control.
Bilirubin and bile acid plasma concentrations
Blood samples from subjects were obtained shortly before the
endoscopic procedure. Bilirubin plasma concentrations were
measured by a modified Malloy-Evelyn method (BIL-T;
Roche Diagnostics, Mannheim, Germany). Fasting plasma
levels of bile acids were determined as described previously.19
Table 2 Primers and probes for TaqMan analysis
Gene Primer Sequence
Villin (VIL1) Forward primer 59-CATGAGCCATGCGCTGAAC-39
Probe 59-TCATCAAAGCCAAGCAGTACCCACCAAG-39
Reverse primer 59-TCATTCTGCACCTCCACCTGT-39
ASBT (SLC10A2) Forward primer 59-ACGCAGCTATGTTCCACCATC-39
Probe 59-TTCAGCTCTCCTTCACTCCTGAGGAGCTC-39
Reverse primer 59-GCGGGAAGGTGAATACGACA-39
MRP2 (ABCC2) Forward primer 59-ACTGTTGGCTTTGTTCTGTCCA-39
Probe 59-CTCAATATCACACAAACCCTGAACTGGCTG-39
Reverse primer 59-CAACAGCCACAATGTTGGTCTCTA-39
MRP3 (ABCC3) Forward primer 59-GGTGGATGCCAACCAGAGAA-39
Probe 59-CCAACCGGTGGCTGAGCATCG-39
Reverse primer 59-GCAGTTCCCCACGAACTCC-39
PPAR-a Forward primer 59-CATTACGGAGTCCACGCGT-39
Probe 59-AGGCTGCAAGGGCTTCTTTCGGC-39
Reverse primer 59-ACACCAGCTTGAGTCGAATCG-39
ASBT, apical sodium dependent bile acid transporter; MRP, multidrug resistance associated protein; PPARa,
peroxisome proliferator activated receptor a.
Table 3 Primers for cDNA standards
Gene Primer Sequence
Villin (VIL1) Forward primer 59-AGAAAGCCAATGAGCAGGAGAA-39
Reverse primer 59-ATGGATGTGGCATCGAACTTC-39
ASBT (SLC10A2) Forward primer 59-CATCTCTGGTTGCTCTCGTTGTTC-39
Reverse primer 59-TGATGTCTACTTTTCGTCAGGTTGAA-39
MRP2 (ABCC2) Forward primer 59-CCAATCTACTCTCACTTCAGCGAGA-39
Reverse primer 59-AGATCCAGCTCAGGTCGGTACC-39
MRP3 (ABCC3) Forward primer 59-TCTATGCAGCCACATCACGG-39
Reverse primer 59-GTCACCTGCAAGGAGTAGGACAC-39
PPARa Forward primer 59-AGGAAGCTGTCCTGGCTCAG-39
Reverse primer 59-CGTCCAAAACGAATCGCG-39
ASBT, apical sodium dependent bile acid transporter; MRP, multidrug resistance associated protein; PPARa,
peroxisome proliferator activated receptor a.
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In brief, bile acids were extracted with Bond-Elut C18
cartridges (Analytichem International, San Diego,
California, USA), solvolysis was performed to cleave sulphate
groups, and enzymatic hydrolysis was performed to deconju-
gate bile acid amidates. Deconjugated bile acids were isolated
by extraction on Lipidex 1000 (Packard Instruments,
Groningen, the Netherlands) and were then methylated
and trimethylsilylated for gas chromatography. Capillary gas
chromatography was performed using a Carlo Erba Fractovap
4160 gas chromatograph (Carlo Erba Instruments, Hofheim,
Germany). Bile acid derivatives were separated on a fused
silica capillary CP Sil 19 CB column coated with chemically
bonded OV-1701 (25 m60.33 mm; Chrompack, Middelburg,
the Netherlands). Hydrogen was the carrier gas (P = 0.6 kg/
cm2). A temperature programme from 140 C˚ to 270 C˚ with 8 /˚
min was started after on-column injection. Eluted bile acid
derivates were detected by a flame ionisation detector.
Fasting plasma samples were stored at 220 C˚ until analysed.
Statistics
All values are expressed as means (SEM). The impact of
different parameters (bilirubin and bile acid concentration,
body mass index, age, and sex) on the variability of ASBT
expression was investigated by multilinear regression analy-
sis. ASBT expression in icteric patients was compared with
that of healthy controls by analysis of variance (ANOVA).
Regional ASBT mRNA expression was compared with
expression in the duodenum by repeated measurement
ANOVA with linear contrasts. Correlation of serum bilirubin
and bile acid concentrations was performed using
Spearman’s rank correlation coefficient (rho). Differences
in demographic characteristics between icteric patients and
controls were analysed by ANOVA of the x2 test, as
appropriate. All comparisons were performed as two sided
comparisons using the SPSS for Windows software (version
12.0). Level of significance was p,0.05
RESULTS
Expression pattern of ASBT mRNA in the human
intestine
Human ASBT mRNA expression was studied in 14 control
subjects (seven women and seven men) who were under-
going a combined gastroscopy and colonoscopy. Results were
normalised by calculation of the ASBT/villin ratio.
Normalised ASBT expression (mean (SEM) arbitrary units)
was 171.8 (20.3) in the duodenum, 1010 (330) in the
terminal ileum, 8.3 (5) in the ascending colon, 4.9 (0.9) in the
transverse colon, 4.8 (1.7) in the descending colon, and 1.1
(0.2) in the sigmoid colon, respectively (fig 1).
Duodenal expression of ASBT mRNA and PPARa
mRNA
Adaptive regulation of ASBT expression in obstructive
cholestasis was investigated by quantification of ASBT
mRNA levels in duodenal biopsies of 20 patients with
obstructive cholestasis and compared with levels obtained
in 14 control subjects. As shown in fig 2, ASBT mRNA
expression (ASBT/villin ratio (mean (SEM)) was about
fourfold lower in patients with obstructive cholestasis (37.9
(6.5)) compared with control subjects (171.8 (20.3);
p,0.001). Patients with obstructive cholestasis due to a
tumour showed a trend for lower ASBT mRNA expression
compared with patients with a benign aetiology of obstruc-
tive cholestasis (31.2 (7.3) for tumour induced and 44.6
(10.8) for benign obstruction); however, the difference was
not statistically significant. Plasma bilirubin levels were 301.6
(64.9) and 112.6 (20.0) mmol/l (p = 0.02) and bile acid levels
were 168.4 (45.3) and 76.8 (22.8) mmol/l (NS) for patients
with and without tumours, respectively. PPARa mRNA
expression was not significantly different between cholestatic
patients and controls.
Correlation of duodenal ASBT mRNA expression with
bilirubin and bile acid plasma concentration
Bilirubin and bile acid plasma concentrations were inversely
correlated with ASBT mRNA expression (rho =20.863,
p,0.001 and rho =20.722, p,0.001, respectively). The
correlation with ASBT mRNA expression was similar for
bilirubin and bile acid concentrations. Using ASBT mRNA
expression, an almost perfect separation was obtained
between icteric patients and healthy controls (fig 3A, B).
Effect of reconstitution of bile flow on ASBT mRNA
expression
In five of the 20 icteric patients, follow up gastroscopy was
performed between 10 and 34 weeks after reconstitution of
bile flow (follow up endoscopy was only performed when
medically indicated). Three of the five patients received stents
into the common bile duct and two patients had a Whipple
operation, one due to a tumour in the head of the pancreas
and one due to a cholangiocarcinoma. The patient who had
the Whipple operation due to a tumour in the head of the
pancreas could not be included in the follow up analysis
because duodenal biopsies could not be obtained after
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Figure 1 mRNA expression of apical sodium dependent bile acid
transporter (ASBT) in different gut segments. Data represent the means
(SEM) of biopsies from 14 healthy subjects. AU, arbitrary units.
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Figure 2 Comparison of apical sodium dependent bile acid transporter
(ASBT) mRNA expression in patients with obstructive cholestasis (n = 20)
compared with control subjects (n = 14) and follow up patients (n = 4).
Data are means (SEM). In the scatterplot, lines connect individual ASBT
mRNA expression pre- and post reconstitution of bile flow in four follow
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complete duodenopancreatectomy. In the patient with
cholangiocarcinoma, only a partial duodenopancreatectomy
was performed so duodenal biopsies were obtained in the
follow up endoscopy.
At follow up endoscopy, bilirubin and bile acid plasma
concentrations had normalised in all patients and three of the
four patients showed increased expression of ASBT mRNA
compared with the baseline value obtained. These three
follow up patients with bilirubin (bile acid) plasma concen-
trations of 373 (431), 170 (204), and 115 (170) mmol/l before
endoscopic intervention showed an increase in ASBT expres-
sion from 73 to 103, 29 to 68, and 71 to 157 after
reconstitution of bile flow, respectively. One patient, who
had a bilirubin (bile acid) level of 65 (32.2) mmol/l before
intervention and 24 (14.5) mmol/l after reconstitution of bile
flow showed an ASBT expression of 130 before intervention,
which decreased slightly to 122 after reconstitution of bile
flow (n = 4). The difference in ASBT expression before (76
(18)) and after (113 (18)) reconstitution of bile flow for these
four follow up patients was not significant (paired t test;
p = 0.15).
Immunohistochemistry of ASBT
Immunohistochemistry analysis in healthy subjects revealed
clear staining of ASBT in ileal and duodenal mucosa (fig 4A
and B, respectively). Staining of duodenal mucosa was clearly
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Figure 3 Individual correlation of bilirubin (A) and bile acid (B) plasma concentrations with apical sodium dependent bile acid transporter (ASBT)
mRNA expression in patients with obstructive cholestasis and control subjects. Data are means (SEM). Arrows connect individual values pre- and post
reconstitution of bile flow in four follow up patients. AU, arbitrary units.
Figure 4 (A–D) Immunohistochemical localisation of apical sodium dependent bile acid transporter (ASBT) protein on the apical membrane of the
ileum and duodenum of humans using a polyclonal rabbit antihuman ASBT antibody. Clear staining of ileal (A) and duodenal (B) epithelial cells of
control subjects. Staining of duodenal epithelial cells in a patient with obstructive cholestasis was almost abolished before (C) and restored after (D)
reconstitution of bile flow (all pictures at 200-fold magnification).
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less intense than that from ileal tissue. In the duodenal
mucosa of icteric patients, staining for ASBT was almost
completely abolished (fig 4C). After reconstitution of bile
flow, a more intense staining was found in the same tissue
(fig 4D).
Duodenal expression of MRP2 mRNA and MRP3 mRNA
Additionally, we investigated whether there was also
adaptive regulation of MRP2 and MRP3 mRNA expression
in the distal part of the duodenum.
Patients with obstructive cholestasis showed significantly
lower MRP2 mRNA expression (0.21 (0.02)) compared with
control subjects (0.32 (0.03), p = 0.004). After reconstitution
of bile flow in four patients with obstructive cholestasis,
MRP2 expression increased to 0.28 (0.02) (NS). No difference
between patients with obstructive cholestasis and control
subjects was observed with regard to MRP3 expression (data
not shown).
DISCUSSION
Bile acids undergo extensive enterohepatic and cholehepatic
circulation through the coordinated action of several trans-
port proteins in hepatocytes, cholangiocytes, and entero-
cytes.20 The uptake of bile acids at the apical membrane of
enterocytes by the apical sodium dependent bile acid
transporter ASBT (SLC10A2) reflects an important mechan-
ism for enterohepatic circulation of bile acids. Human ASBT
is an efficient transport system for conjugated and unconju-
gated bile acids.3 In the present study we were able to show
that human ASBT mRNA and protein are expressed in the
duodenum of the human intestine but to a lesser extent than
in the terminal ileum. In addition, significant downregula-
tion of duodenal ASBT mRNA expression was demonstrated
in patients with complete or near complete obstruction of bile
duct compared with control subjects. Finally, restoring bile
flow to the duodenum increased ASBT mRNA expression in a
subpopulation of patients with bile duct obstruction.
Downregulation of human duodenal ASBT mRNA may be
compared with the adaptive response of bile acid transport
proteins during obstructive cholestasis in the terminal ileum,
the kidney, as well as in the cholangiocytes of the rat.11 21 In
addition to downregulation of asbt in the terminal ileum, the
intestinal absorption rate of taurocholate in bile duct ligated
rats was lower and the absorption rate was inversely
correlated to serum bile acid concentrations compared with
sham operated rats.11 Patients with mutations in the ASBT
gene can suffer from congenital diarrhoea and steatorrhoea,
which is explained by an interrupted enterohepatic bile acid
circulation.4 Further clinical data indicate that in patients
with primary sclerosing cholangitis, biliary enrichment of
UDCA decreases with increasing cholestasis.22 Moreover, in
patients with bile duct obstruction and external biliary
drainage, intestinal absorption of UDCA was decreased,
before relief of cholestasis.23 These data suggest that in
humans, intestinal bile acid absorption is reduced during
obstructive cholestasis.
What factors influence ASBT gene expression in the
enterocyte are largely unknown. Animal studies suggest that
luminal bile acids may be one such regulatory factor.
Reduction of intestinal bile acid concentration during
fasting24 or after biliary diversion25 or bile duct ligation26 is
accompanied by a decrease in ileal bile acid transport.
Stravitz et al demonstrated that increasing intestinal bile
acid concentrations by cholic acid feeding leads to an increase
in the sodium dependent transport rate.10 Furthermore,
adaptive induction of asbt mRNA levels and transporter
protein as well as increased asbt transport activity by cholic
acid fed rats was documented.10
In contrast with these observations, other authors have
demonstrated in rats that the ileal taurocholate absorption
rate correlated inversely to serum bile acid concentrations
after bile duct ligation and after biliary diversion compared
with sham operated animals.11 The authors concluded that
cholestasis leads to decreased, and biliary diversion to
increased, active ileal absorption of taurocholate, in which
the systemic bile acid load seems to be the decisive factor. In
the kidney, bile acid excretion in urine increased progres-
sively in both cholestatic animal models but also in clinical
cholestatic disorders.21 27 In Wistar rats, a marked reduction
in asbt protein expression in microsomal membrane fractions
from whole kidney after CBDL was observed, resulting in
reduced levels of asbt expression on the luminal membrane
of the proximal tubule of the kidney, a change that is
associated with a diminished capacity to reabsorb bile acids
from the glomerular filtrate.21 In the same study, upregula-
tion of Mrp2 protein expression on the apical membrane of
the rat renal proximal tubule was shown. MRP2 is associated
with an increased ability to excrete divalent organic anions
such as bile salt sulphates and glucuronides (bilirubin) that
accumulate during cholestasis and would therefore facilitate
extrahepatic pathways for bile acid and bilirubin excretion
during cholestasis. This adaptive response of asbt and Mrp2
in the kidney of the rat does not seem to be regulated by
luminal bile acids.
Here we showed that ASBT mRNA expression correlated
inversely with bilirubin as well as with bile acid plasma
concentrations, which were both used as markers for
obstructive cholestasis.
Bile acids are synthesised from cholesterol in the liver;
their production is a major mechanism of cholesterol
elimination and important for the maintenance of cholesterol
homeostasis.28 Downregulation of ASBT expression in
obstructive cholestasis might therefore be of clinical interest.
In a previous publication, it was shown that inhibition of ileal
bile acid transport with SC-435, a competitive inhibitor of
ASBT, lowered plasma cholesterol levels: (1) by inactivating
the hepatic farnesoid x receptor and (2) by stimulating
cholesterol 7a-hydroxylase (CYP7A1).29 This cytochrome is
the rate limiting enzyme of chenodeoxycholic acid synthesis.
It is located in the endoplasmic reticulum of the hepatocyte.
In patients with biliary obstruction, a rise in serum
7a-hydroxycholesterol was observed after biliary drainage.30
The 7a-hydroxylation rate was significantly lower for patients
with obstructive cholestasis compared with healthy sub-
jects.31 These data suggest that in the case of a substantial bile
acid malabsorption, the activity of 7a-hydroxylase in the liver
and synthesis of bile acids is increased.
Other authors suggest that inhibition of ASBT with SC-435
reduces low density lipoprotein cholesterol and ApoB by
enhanced plasma clearance of low density lipoprotein
ApoB.6 9 Treatment of Caco-2 cell monolayers with
25-hydroxycholesterol significantly inhibited Na+ dependent
3H-taurocholate uptake. Inhibition in hASBT activity was
associated with reduction in both the level of hASBT mRNA
and its promoter activity.32 asbt protein expression did not
change in rats but rose by 31% in rabbits when they were fed
with cholesterol (cholest-5-en-3b-ol).33 Administration of
SC-435 to apo E2/2 mice lowered serum total cholesterol by
35% and reduced aortic root lesion area by 65%. The authors
concluded that specific inhibition of abst could be a novel
therapeutic approach for treatment of hypercholesterolaemia,
resulting in a decreased risk for atherosclerosis.7 Taken
together, all of these data suggest that expression of ASBT
in the enterocyte seems to be an important component in
cholesterol homeostasis and lipid metabolism in humans.
Intracellular factors that influence ASBT gene expression
remain largely unknown. One potential factor might be
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activation of nuclear receptor PPARa, a ligand activated
transcription factor that regulates expression of a number of
genes involved in peroxisomal and mitochondrial b-oxidation
of fatty acids. PPARa binds as a heterodimer with the
retinoid X receptor to a peroxisome proliferator response
element located in the promoter region of target genes.
PPARa was shown to play a critical role in the adaptive
response to fasting in mice.34–36 PPARa also influences bile
acid composition by induction of the sterol 12a-hydroxylase,
which acts at a branch-point in the bile acid synthetic
pathway by catalysing the conversion of 7a-hydroxy-4-
cholesten-3-one to 7a,12a-dihydroxy-4-cholesten-3-one.
This reaction determines the ratio of cholic acid to
chenodeoxycholic acid.37 In Hepa 1c1c7 cells, which were
transiently transfected with an expression plasmid for PPARa
and retinoid X receptor a and a luciferase reporter construct
containing copies of the peroxisome proliferator response
element from the rat ACOX gene, inhibition of PPARa
reporter gene expression was shown with increasing con-
centrations of chenodeoxycholic acid in the presence or
absence of Wy-14,643 ( = PPARa ligand).38 It was concluded
that during certain pathophysiological states, where intra-
cellular bile acid concentrations might be elevated, effects on
PPARa dependent target gene regulation are possible.38
Recently, PPARa was shown to transactivate the human
ASBT gene.39 Incubation of human hepatoma HepG2 cells
with chenodeoxycholic acid resulted in significant induction
in PPARa mRNA levels. In addition, hPPARa gene expression
was upregulated by taurocholic acid in human primary
hepatocytes.40 However, no difference between patients with
obstructive cholestasis and control subjects was observed
with regard to duodenal PPARa mRNA expression in our
study.
In a previous study, Dietrich et al demonstrated that
obstructive cholestasis promotes downregulation of intestinal
MRP2 protein expression in rats and humans.15 The reduction
was correlated with duration of cholestasis and was
reversible after reconstitution of bile flow. In the same study,
in patients with obstructive cholestasis, a non-significant
decrease in MRP2 mRNA expression was detected compared
with control subjects. However, the authors observed that
decline of intestinal rat Mrp2 mRNA occurred more slowly
and gradually than downregulation of its protein expression.
Our results showed a significant downregulation of MRP2
mRNA expression compared with control subjects and a non-
significant increase after reconstitution of bile flow in four
patients. One explanation for the downregulation of MRP2
gene expression in our study compared with Dietrich and
colleagues15 might be higher plasma bilirubin concentrations
in our patients with obstructive cholestasis. Another reason
might be duration of cholestasis, which was not clearly stated
in both studies and therefore may have been different. Other
factors such as food derived compounds or substrates might
also be involved in the regulation of gene expression. For
example, it was shown that grapefruit and orange juice
inhibited the transport by MRP2,41 components of our daily
diet, such as the flavenoid epicatechin in tea,42 chrysin, and
its metabolites are substrates of MRP2.43 Drugs are unlikely to
have contributed to the different MRP2 mRNA expression in
the present study and the study performed by Dietrich and
colleagues15 because patients with drugs, which are known to
affect MRP2 expression, were excluded from both studies.
Finally, our data support the results of Dietrich and
colleagues15 which demonstrated an adaptive downregulation
of duodenal MRP2 in patients with obstructive cholestasis.
MRP3 is expressed on the basolateral membrane in the
proximal small bowel13 and is capable of transporting bile
salts, including taurocholate, glycocholate, taurochenodeoxy-
cholate-3-sulphate, and taurolithocholate-3-sulphate.14 This
suggests that MRP3 might be an important transporter in the
enterohepatic circulation of bile acids. However, in the
present study, we did not observe any difference in human
duodenal MRP3 gene expression in patients with obstructive
cholestasis compared with control subjects. Similarly, no
compensatory upregulation of human duodenal MRP3
expression in cholestatic patients was previously described.15
In conclusion, human ASBT mRNA is expressed in the
small intestine, predominantly in the terminal ileum but also,
to a lesser extent, in the duodenum. Adaptive downregula-
tion of ASBT and MRP2 mRNA in the duodenum can be
observed in patients with obstructive cholestasis compared
with control subjects. Furthermore, duodenal ASBT mRNA
expression levels inversely correlated with bilirubin and bile
acid plasma concentrations in patients with obstructive
cholestasis as well as in control subjects. This adaptive gene
regulation may represent a mechanism preventing the
accumulation of hepatotoxic bile acids in cholestasis. After
relief of cholestasis, an increase in ASBT mRNA was observed
in three of four patients.
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